Clostridium difficile infection (CDI) is a clinical syndrome typically characterized by loose, frequent bowel movements and abdominal pain, which occur as a result of toxin production by colonic C difficile.
Clostridium difficile infection (CDI) is a clinical syndrome typically characterized by loose, frequent bowel movements and abdominal pain, which occur as a result of toxin production by colonic C difficile. [1] [2] [3] [4] CDI occurs in patients colonized with toxigenic C difficile and in patients who have newly acquired C difficile. Estimates of the relative contributions of persistent colonization and new acquisition to incident CDI vary. 5, 6 In both cases, the pathogenesis of CDI involves depletion of non-C difficile colonic microbiota, altered bile acid metabolism, germination of (resident or recently ingested) C difficile spores, expansion of a population of vegetative C difficile, toxin production, and colonic inflammation.
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ABBREVIATIONS: CDI = Clostridium difficile infection; EIA = enzyme immunoassay; FDA = Food and Drug Administration; FMT = fecal microbiota transplantation; GDH = glutamate dehydrogenase; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; IND = Investigational New Drug; MDRO = multidrug-resistant organism; NAAT = nucleic acid amplification test; R-CDI = recurrent C difficile infection; SC-CDI = severe complicated C difficile infection
The primary event in CDI pathogenesis appears to be depletion of non-C difficile colonic microbiota with a loss of colonization resistance and a concomitant increase in C difficile spore germination. 8, [13] [14] [15] [16] The risk factors known to correlate with risk for C difficile colonization and CDI-antibiotic exposure, gastric acid suppression (with proton pump inhibitors, in particular), and age-each plausibly contributes to this process. [17] [18] [19] [20] Consistent with current understanding of CDI pathogenesis, delivery of colonic microbiota from a healthy donor, or fecal microbiota transplantation (FMT), long has been known to eliminate the symptoms of CDI. [21] [22] [23] [24] [25] [26] Such treatment appears to succeed in relieving the symptoms of CDI in proportion to its success in reconstituting the bacterial community of the donor, though complete engraftment is not necessary, and microbes other than bacteria may play a role as well.
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The first-line treatment for CDI remains anti-C difficile antibiotics (metronidazole, oral vancomycin, or fidaxomicin).
2,3 Treatment of CDI with anti-C difficile
antibiotics is typically successful in relieving CDI symptoms, but anti-C difficile antibiotics may suppress other colonic microbiota, and C difficile may persist for months as a spore. As many as 20% of CDI cases treated with anti-C difficile antibiotics recur, and the risk of recurrent CDI (R-CDI) increases with each subsequent CDI episode. 38 The typical clinical manifestation of CDI includes abdominal pain and cramping accompanied by frequent, watery stools. 1, 66 Melena and hematochezia are rare.
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Signs of a systemic inflammatory response to colitis, including fever and leukocytosis, may be present, and the presence of such symptoms defines severe complicated CDI (SC-CDI). Symptoms typically improve within a week of starting appropriate anti-CDI antibiotics, though dose escalation may be required to induce a response in some cases. 3 Postinfectious irritable bowel syndrome (IBS), which can occur in the post-CDI period even after successful CDI treatment and may include prominent lactose intolerance, sometimes interferes with the full resolution of GI symptoms. 68 The diagnosis of CDI typically is based on (1) NAAT, FMT also may be considered for cases of refractory CDI or SC-CDI. Refractory CDI, or CDI unresponsive to high-dose oral vancomycin or fidaxomicin, often fits the criteria for SC-CDI (ie, associated with hypotension, fever, ileus, abdominal distention, mental status change, leukocytosis or leukopenia, elevated serum lactate levels, end-organ dysfunction, or requiring intensive care unit admission). 3 Randomized clinical trial data are lacking to guide FMT treatment for SC-CDI. Observational studies suggest a possible benefit from FMT, but there is debate as to the optimal FMT dosing regimen in this population; some reports suggest that patients with SC-CDI may benefit from multiple serial FMT procedures (as opposed to a single FMT procedure, the standard for R-CDI) or from continuation of anti-CDI antibiotics concurrent with FMT (as opposed to prior cessation of antibiotics, the standard for R-CDI). [75] [76] [77] [78] [79] The decision to proceed with FMT in SC-CDI must take into account uncertainty regarding the optimal FMT strategy this population, as well as uncertainty regarding whether the expected benefit matches that of FMT for R-CDI.
In our experience, the alternative diagnosis of ischemic colitis should be considered in patients suspected of having SC-CDI, particularly if C difficile test results are equivocal. Ischemic colitis may manifest with symptoms similar to those of SC-CDI, and interaction between C difficile toxin and colonic ischemia may contribute to a more severe manifestation of CDI. Table 1 summarizes a subset of the screening recommendations published by centers with clinical experience and by advisory groups. 22, 47, 50, 88, [91] [92] [93] [94] [95] As standards for donor screening evolve, so do standards for FMT donation processing and storage.
The first, to our knowledge, large randomized controlled trial of FMT used freshly donated stool. 27 Results from subsequent studies have supported the equivalent efficacy of frozen stool preparation. 41, 42, 44 Given the imperative for rigorous donor screening and the difficulty of timing donation, most institutions performing regular FMT have developed local banks of frozen stool preparations or work with outside stool banks such as OpenBiome to provide the same product. 48 Processing donated stool typically involves three steps: (1) homogenization and filtration to remove large particles, (2) concentration of bacteria via centrifugation, and (3) the addition of glycerol to permit frozen storage without bacterial cell lysis, which may impact the viability of bacterial cells and the efficacy of the FMT product. 47, 96, 97 The production of capsulized FMT for oral delivery also may involve the addition of a lipid emulsion so that capsules remain stable for ingestion. 98 A single FMT dose typically uses 50 g of fecal material, but a wide range of masses have been used, and one randomized controlled trial used 100 g of fecal material per dose. 24, 27, 41, 42, 44, 47, 99 It is expected that each gram of stool contains 10 10 to 10 12 bacterial cells.
100,101
The FMT dose can be administered via the upper or lower GI tract. Upper GI delivery methods include oral capsules, nasogastric tubes, nasoduodenal tubes, and esophagogastroduodenoscopy; lower GI delivery methods include colonoscopy, sigmoidoscopy, and enema. Studies directly comparing delivery methods are scarce. Several authors have reported a 5% to 10% greater cure rate with lower GI delivery compared with the rate for upper GI delivery. 41, 76, 99, [102] [103] [104] However, there are reports of cases refractory to lower GI delivery that responded to FMT via oral capsules, 105 and to date, to our knowledge, only a single, small trial has compared upper vs lower GI delivery directly. 41 Each approach has potential adverse effects: FMT delivered in the upper GI tract may not arrive promptly in the colon if CDI is accompanied by ileus, as is often true in SC-CDI. Delivery of FMT by means of lower GI endoscopy or enema may risk perforation if colonic inflammation is advanced, which also may be the case in SC-CDI.
Just as there is little consensus on the optimal mode of FMT delivery, there is little consensus on how best to prepare the recipient prior to FMT. Bowel lavage is known to reduce the luminal bacterial load significantly, 106 but whether it should be performed prior to FMT is uncertain. Large, randomized controlled trials that support the efficacy of FMT for R-CDI have been performed both with bowel lavage prior to FMT 23 and without. 44 It is typical to stop anti-CDI antibiotics 24 to 48 hours prior to the FMT procedure, but the impact of this timing on FMT success has not been evaluated rigorously, nor is there robust evidence to support which anti-CDI antibiotic should be used prior to FMT or at which dose. Some practitioners advocate the use of gastric acid suppression (typically a proton pump inhibitor) for 24 hours prior to upper GI FMT, 22 though this procedure has been used variably in randomized controlled trials. 27, 41, 42 Clinical evidence to determine whether bowel lavage and antacid treatment should be given is lacking, and the optimal pre-FMT bowel lavage, antibiotic, and antacid regimen is unknown.
In a broad array of observational studies and trials, as well as in our own experience, FMT cures > 80% of R-CDI cases with a single dose. Repeat dosing typically achieves cure in > 90% of patients with R-CDI. 3 
Clinical history
Physician concern prompted by health history and lifestyle screen
Exposure to HIV, viral hepatitis (within 12 mo)
Tattoo or body piercing (within 6 mo)
Travel to areas with endemic diarrheal diseases (within 6 mo)
History of IBS, idiopathic chronic constipation, or chronic diarrhea
History of GI malignancy or known polyposis
Recent ingestion of a potential allergen (recipient with allergy)
History of major GI surgery (eg, gastric bypass)
Systemic autoimmunity (MS, SLE, and so on)
Atopic diseases (asthma and eczema, eosinophilic GI disorders)
Chronic pain syndromes (fibromyalgia, chronic fatigue)
Risk for MDROs, including clinical work 
Ova and parasites at microscopy
Vancomycin-resistant Enterococcus screen
Extended-spectrum beta-lactamase screen
Carbapenemase-producing enterobacteriaceae screen
Serologic and other testing
Malaria and babesiosis screen . . þ . .
Gonorrhea and chlamydia screen
chestjournal.org secondary prevention of CDI recurrence failed to demonstrate an advantage over prolonged use of oral vancomycin.
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It is essential to inform patients seeking FMT for R-CDI not only of the probability of treatment success but also of the symptoms to be expected after the procedure. [112] [113] [114] In the first 24 hours after FMT, bloating, flatulence, and loose stools are common. These symptoms typically resolve quickly, though some patients complain of bloating and flatulence for weeks. IBS following CDI and after FMT is well documented and may be characterized by lactose intolerance. Diarrhea may recur on isolated days, but patients whose FMTs are successful typically progress to formed stools over 1 to 2 weeks. Early FMT failure is far more common than late FMT failure: A recent cohort study found the rate of early (within 1 month) failure to be 18.6% and of late (1-3 months after FMT) failure to be 2.7%. 109 Failure typically manifests as recurrent diarrhea that progresses over several consecutive days. Such symptoms should prompt repeat stool testing for C difficile. Some practitioners advocate routine post-FMT stool testing, but we have avoided this practice given the uncertain significance of persistent positive NAAT results, as discussed.
The primary alternative to FMT for R-CDI is a prolonged antibiotic taper with pulsed dosing, which commonly is paired with a high-dose probiotic such as kefir. 71, 115 The monoclonal antibody bezlotoxumab has been shown to reduce the risk of CDI recurrence when administered with standard antibiotic therapy for CDI, but its optimal use in secondary prevention of R-CDI
has not yet been established. [116] [117] [118] The primary alternative to FMT for SC-CDI is surgery, either colectomy or diverting loop ileostomy with colonic lavage. 119 The details of these treatments are beyond the scope of this review.
Impact of FMT Beyond CDI
FMT is an effective means for treating CDI, particularly R-CDI. Its use for the treatment of other diseases is an area of active exploration. When advising FMT for the treatment of CDI in patients with other underlying bowel disease, it is essential to consider the potential for off-target FMT effects. In particular, FMT may impact IBD activity.
Whether FMT aids IBD control or provokes IBD exacerbation is an area of active debate, and at present no conclusive statement can be made on the balance between FMT's benefits and risks in this population. Several studies have been performed to evaluate the efficacy of FMT as a treatment for IBD, and they have produced conflicting results. Reports of FMT benefitting patients with IBD include remission rates as high as 27%, [120] [121] [122] but reports suggesting benefit have been matched by reports of adverse events that may be attributable to FMT, including IBD exacerbation and microscopic colitis. 108, 123, 124 The possibility of IBD exacerbation induced by FMT should highlight the importance of discriminating CDI from IBD. 68 FMT from donors without recent antibiotic exposure also has been observed to reduce colonization by multidrug-resistant organisms (MDROs), and mechanisms by which FMT contributes to MDRO colonization resistance have been proposed. [125] [126] [127] [128] [129] [130] [131] This off-target effect appears purely beneficial, but its impact on subsequent risk for MDRO infection has not been studied thoroughly. Until the impact of FMT on the risk for subsequent MDRO infection is better characterized, this potential benefit should not sway the decision on whether to proceed with FMT.
Infrastructure for Clinical FMT: Oversight, Billing, and Anticipated Changes
The greatest impediments to the broad dissemination of FMT for the treatment of R-CDI are uncertainty surrounding regulation by the FDA and the difficulty of obtaining reimbursement. Present regulation is not unduly onerous for FMT practitioners, but the FDA is reviewing its FMT guidance. The FDA considers FMT an investigational drug but declared in 2013 that it would exercise "enforcement discretion" and not require an Investigational New Drug (IND) application from physicians who perform FMT for the treatment of CDI that does not respond to anti-CDI antibiotics. 52 The consideration of FMT as a drug places it under the "Guidance for Industry: Enforcement Policy Regarding Investigational New Drugs" 132 rather than the regulations that the FDA uses for the oversight of blood transfusions (including donor screening, blood testing, donor deferral lists, quarantine, and regulations to address deficiencies), which might be more appropriate.
An IND application is required if FMT is to be performed for any indication other than CDI, and such treatment should be performed only in the setting of a clinical trial. 39, 40 In March 2016, the FDA announced an intention to revise its FMT oversight, with specific consideration given to IND application requirements for large stool banks. 132 The revised policy has not yet been finalized.
Cost-effectiveness analyses have demonstrated substantial cost savings and increased efficacy of FMT for R-CDI, relative to those for oral vancomycin therapy. [133] [134] [135] Despite these data, in our experience, insurance reimbursement for FMT is not reliable, and reimbursement rates rarely cover the substantial cost of donor screening or purchase of the FMT dose from a stool bank. If FMT donation processing and dose administration are performed by the FMT practitioner, two Current Procedural Terminology codes can be billed: 44705 for the preparation of fecal microbiota for instillation (alternative for Medicare: G0455) and 44799 for the FMT instillation via naso-or oroenteric tube or enema. Esophagogastroduodenoscopy and colonoscopy should be billed as they would be normally. If the FMT material is obtained from a stool bank, it is recommended that code J3590 ("unclassified biologics") be used in lieu of 44705 and 44799, but no reimbursement is to be expected from this code. 136 
Conclusions
We have reviewed the clinical application of FMT for the treatment of CDI, paying particular attention to the care that must be taken in determining eligibility for FMT, the (evolving) present standards for FMT preparation and administration, the uncertainty of FMT regulation and difficulty of FMT billing, as well as emerging data on FMT effects beyond CDI. FMT has revolutionized the treatment of R-CDI, but much work remains to be done in defining the optimal FMT dose, as well as optimal protocols for donor screening, recipient preparation, and post-FMT monitoring. We remain in the early stages of establishing FMT's role in the treatment of SC-CDI, early CDI, and other bowel diseases. Given the benefits that FMT has demonstrated already, it is imperative that work to improve FMT efficacy and extend its benefits proceed rapidly.
